Myriad Genetics, Inc.
NASDAQ:MYGNMedical - Diagnostics & Research
+$0.14 today
- Market cap
- $530.45M
- Beta
- 1.64
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$4.27
Volume 1.26M
Average 1.81M
MYGN EBITDA Margin
EBITDA as a percentage of revenue.
Myriad Genetics, Inc.NASDAQ: MYGN
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin narrows to -8.7%
EBITDA Margin was -8.7% in Q1 FY2026, down 1.5 pp from a year earlier. On a trailing-twelve-month basis it was -40.3%, down 32.6 pp year over year. Over 3 fiscal years it narrowed by 27.6 pp.
Context
- EBITDA Margin widened in 1 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 5 analysts of -1.2% for the fiscal year ending Dec 2026, up from -40.1% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -8.7%-12.6 pp QoQ
- Last fiscal yearDec 2025
- -40.1%-33.0 pp YoY
- LTMMar 2026
- -40.3%-32.6 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -40.1%
- Year-over-year change
- -33.0pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -40.1% | -33.0pp |
| FY2024 | 2024-12-31 | -7.1% | +19.1pp |
| FY2023 | 2023-12-31 | -26.2% | -13.7pp |
| FY2022 | 2022-12-31 | -12.5% | -14.3pp |
| FY2021 | 2021-12-31 | 1.8% | — |
EBITDA Margin vs competitors
How MYGN compares with its peers on the latest reported figures
- MYGN's LTM Mar 2026 EBITDA Margin of -40.3% is the 8th highest of the 10 companies compared; the peer median is -6.6%.
- Its year-over-year change of -32.6 pp is the 8th highest of 10, against a peer median of +4.2 pp.
- Over three fiscal years its change of -27.6 pp compares with a peer median of +20.8 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 33.5% | -1.6 pp | -2.1 pp | |
| LTM Jun 2026 | 23.1% | +13.6 pp | +20.8 pp | |
BLLNBillionToOne, Inc. | LTM Jun 2026 | 12.6% | +21.8 pp | — |
| LTM Jun 2026 | 1.7% | +5.8 pp | +10.8 pp | |
| LTM Jun 2026 | -6.6% | +4.2 pp | +53.9 pp | |
| LTM Mar 2026 | -18.3% | -9.7 pp | -49.4 pp | |
| LTM Sep 2026 | -34.5% | +4.7 pp | +98.7 pp | |
| LTM Mar 2026 | -40.3% | -32.6 pp | -27.6 pp | |
| LTM Mar 2026 | -132.6% | -47.0 pp | — | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | -2329.5% | -862.2 pp | +207.6 pp |
| Peer median (excluding MYGN) | -6.6% | +4.2 pp | +20.8 pp | |
Competitors are the stored peer set for MYGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 690.6M | 678.4M | 753.2M | 837.6M | 824.5M |
| Cost of Revenue | 197.6M | 202M | 236.2M | 252.2M | 247.9M |
| Gross Profit | 493M | 476.4M | 517M | 585.4M | 576.6M |
| Gross Margin | 71.4% | 70.2% | 68.6% | 69.9% | 69.9% |
| Research & Development | 81.9M | 85.4M | 88.7M | 113.4M | 106.8M |
| Selling, General & Admin | 537.8M | 514.7M | 572.9M | 560M | 537.6M |
| Operating Expenses | 683.5M | 617M | 774.4M | 708.9M | 644.4M |
| Depreciation & Amortization | 62.8M | 52.7M | 61.9M | 61.2M | 53.7M |
| EBITDA | 12.3M | (84.7M) | (197.4M) | (59.5M) | (330.9M) |
| EBITDA Margin | 1.8% | -12.5% | -26.2% | -7.1% | -40.1% |
| Operating Income | (190.5M) | (140.6M) | (257.4M) | (123.5M) | (67.8M) |
| Operating Margin | -27.6% | -20.7% | -34.2% | -14.7% | -8.2% |
| Interest Income | 700K | 2.6M | 2.5M | 1.7M | 1.8M |
| Interest Expense | 6.6M | 3.2M | 2.9M | 2.8M | 10.5M |
| Other Income / Expenses | 133.4M | (16.9M) | (4.8M) | (35.5M) | (327.3M) |
| Income Before Tax | (57.1M) | (140.6M) | (262.2M) | (123.5M) | (395.1M) |
| Pre-Tax Margin | -8.3% | -20.7% | -34.8% | -14.7% | -47.9% |
| Income Tax Expense | (29.9M) | (28.6M) | 1.1M | 3.8M | (29.2M) |
| Net Income | (27.2M) | (112M) | (263.3M) | (127.3M) | (365.9M) |
| Net Margin | -3.9% | -16.5% | -35.0% | -15.2% | -44.4% |
| EPS (Basic) | (0.35) | (1.39) | (3.18) | (1.41) | (3.96) |
| EPS (Diluted) | (0.35) | (1.39) | (3.18) | (1.41) | (3.96) |
| Weighted Avg Shares | 77.71M | 80.58M | 82.8M | 90.6M | 93.3M |
| Weighted Avg Shares (Diluted) | 78M | 80.6M | 82.8M | 90.6M | 93.3M |
Myriad Genetics, Inc.
NASDAQ:MYGN
Intrinsic Alpha fair value
Locked
Current Price
$5.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.